ライフサイエンスコーパス: rectal adenocarcinoma

1 doption of minimally invasive techniques for rectal adenocarcinoma.

2 the human rectum after radiation therapy for rectal adenocarcinoma.

3 ctive markers of radiation responsiveness in rectal adenocarcinoma.

4 dictors of overall survival in patients with rectal adenocarcinoma.

5 erapy (RT) in patients with locally advanced rectal adenocarcinoma.

6 properly selected patients with early-stage rectal adenocarcinoma.

7 included 1948 patients with locally advanced rectal adenocarcinoma.

8 pants included patients with stage II or III rectal adenocarcinoma.

9 paradigm for patients with locally advanced rectal adenocarcinoma.

10 s a newly established standard treatment for rectal adenocarcinoma.

11 th mismatch repair-deficient stage II or III rectal adenocarcinoma.

12 ranging from 13% of glioblastomas to 63% of rectal adenocarcinomas.

13 r resection of T3-4, N0, M0 or T1-4, N1, 2M0 rectal adenocarcinoma, 1,917 patients were randomly assi

14 characteristics, treatment, and outcomes of rectal adenocarcinoma across 16 years.

15 rease organ preservation (OP) rate for early rectal adenocarcinoma (ADK) of low-mid rectum.

16 Patients with clinical T3/T4 rectal adenocarcinoma and no evidence of metastases were

17 n consecutive patients with locally advanced rectal adenocarcinoma at a median distance of 6 cm from

18 Patients diagnosed with colon or rectal adenocarcinoma between January 2013 and December

19 T6GAL-1 mRNA was assessed in untreated human rectal adenocarcinoma by PCR assays.

20 age, 62 [19-84] years) with locally advanced rectal adenocarcinoma (clinical tumor stage 3 to 4 and/o

21 ] and 570 women [29%]) with locally advanced rectal adenocarcinoma (cT3 or 4 or cN+) treated within 3

22 ults using The Cancer Genome Atlas colon and rectal adenocarcinoma data (n = 570).

23 Information about primary, invasive rectal adenocarcinomas diagnosed between 1994 to 1996 in

24 patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma eligible for endoscopic resection

25 e (NCDB) to evaluate patients diagnosed with rectal adenocarcinoma from 2004 through 2019.

26 patients with nonmetastatic locally advanced rectal adenocarcinoma from 2010 to 2014, who underwent n

27 performed an investigation of patients with rectal adenocarcinoma from Los Angeles County from 1988

28 Data on 17600 patients with stage II to III rectal adenocarcinoma from the 2006-2012 National Cancer

29 rrheic foal and serially propagated in human rectal adenocarcinoma (HRT-18) cells.

30 Trends in the treatment and outcomes of rectal adenocarcinoma in the US between 2004 and 2019 we

31 ups with the largest divergence in APCs were rectal adenocarcinoma in White vs Black women (APC of 2.

32 g APC (APC, 2.2; 95% CI, 1.6 to 2.8) whereas rectal adenocarcinoma incidence rates among Black indivi

33 Absolute rectal adenocarcinoma incidence rates were 39% lower in

34 Locally advanced (T3-4 and/or N1) rectal adenocarcinoma is commonly treated with preoperat

35 Surgical management for rectal adenocarcinoma is evolving towards utilization of

36 w Zealand randomized 475 patients with T1-T3 rectal adenocarcinoma less than 15 cm from the anal verg

37 phase 3 trial of 475 patients with T1 to T3 rectal adenocarcinoma <15 cm from anal verge, given Lap

38 going low anterior resection (1991-2010) for rectal adenocarcinoma (</=15 cm from anal verge) were re

39 eries included adults (aged >=18 years) with rectal adenocarcinoma managed with curative intent from

40 ondary analysis of the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial, which randomized par

41 ) was examined in the Organ Preservation for Rectal Adenocarcinoma (OPRA) trial.

42 Our study includes 323 locally advanced rectal adenocarcinoma patients treated with LCCRT-based

43 te and prednisolone group (one event each of rectal adenocarcinoma, pulmonary haemorrhage, and a resp

44 cluded patients diagnosed with nonmetastatic rectal adenocarcinoma receiving surgical treatment at Co

45 ll incident cases of invasive, nonmetastatic rectal adenocarcinoma reported to the National Cancer Da

46 A total of 254 pretreatment rectal adenocarcinoma specimens were analyzed in this st

47 had previously untreated, locally advanced, rectal adenocarcinoma, stage IIA-IIIC or IV as per the A

48 Patients with clinical T2N0 rectal adenocarcinoma staged by endorectal ultrasound or

49 88 and October 2003, 27 patients with distal rectal adenocarcinoma staged T2 by clinical and/or endor

50 laparoscopic surgery among 471 patients with rectal adenocarcinoma suitable for curative resection co

51 Among patients with rectal adenocarcinoma suitable for curative resection, r

52 observed after preoperative radiotherapy for rectal adenocarcinoma that might be related, in part, to

53 ril 2014 to March 2020 with stages II or III rectal adenocarcinoma to undergo either induction or con

54 ofiling may assist in response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy

55 s a wide spectrum of tumor responsiveness of rectal adenocarcinomas to preoperative chemoradiotherapy

56 d to analyze 562 patients with nonmetastatic rectal adenocarcinoma treated between 1989 and 2004.

57 utcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherap

58 n, newly diagnosed, primary locally advanced rectal adenocarcinoma treated with SCRT-TNT or LCCRT.

59 s of the Organ Preservation in Patients with Rectal Adenocarcinoma trial, a phase 2, nonblinded, mult

60 I alone is a poor tool to distinguish pCR in rectal adenocarcinoma undergoing TNT.

61 t men, two women; mean age, 72.3 years) with rectal adenocarcinoma underwent two repeated volumetric

62 Three fragments from a single rectal adenocarcinoma were chosen for whole-exome sequen

63 Patients with localized rectal adenocarcinoma were identified in the Surveillanc

64 National Cancer Data Base undergoing LAR for rectal adenocarcinoma were identified.

65 or open rectal resections for stage I to III rectal adenocarcinoma were included from the National Ca

66 A total of 318 548 patients diagnosed with rectal adenocarcinoma were included in the analysis, 191

67 Patients with cT3-4 and/or node-positive rectal adenocarcinoma were included in the analysis.

68 from 2007 to 2011 with stage II/III primary rectal adenocarcinoma were selected from surveillance, e

69 Patients with locally advanced rectal adenocarcinoma were treated with preoperative CRT

70 A total of 110 571 patients (59.3% men) with rectal adenocarcinoma who underwent curative-intent surg

71 ation on all patients with stage pT1 and pT2 rectal adenocarcinoma who underwent local excision from

72 ive study included consecutive patients with rectal adenocarcinoma who underwent total neoadjuvant th

73 complex landscape of therapeutic options for rectal adenocarcinoma with a focus to accomplish this qu

74 ember 2008 and September 2011, patients with rectal adenocarcinoma within 12 cm from the anal verge,

75 Eligible patients had clinical-stage T3 rectal adenocarcinoma within 12 cm of the anal verge wit

76 included patients of all ages diagnosed with rectal adenocarcinoma without distant metastases who had